On June 14, 2023 Maru Therapeutics reported the company signed a business agreement with TS Bio on May 8 for joint research and development of CAR-NK cell therapy (Press release, Maru Therapeutics, JUN 14, 2023, View Source [SID1234643988]). Accordingly, the two companies plan to establish a strategy for the development of blood-based CAR-NK cell therapy and begin full-scale cooperation for (non-)clinical research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell manufacturing (CMO) during the joint research and development process between the two companies is planned to be carried out at TS Bio’s central research center at the GMP level.

Maru Therapeutics CEO Sangman Ahn said, "Maru’s innovative platform technology has the scalability to be applied to various immune cells and carcinomas," and added, "Through this collaboration, we will not only expand our R&D area with TS Bio, but also accelerate development." "We will accelerate it," he said.